In this podcast, expert clinicians will discuss current and future approaches for the management of patients with uveitis.
In this podcast, expert clinicians will discuss the utilization of surgery in the management of patients with retinal diseases.
In this podcast, expert clinicians will discuss the utilization of imaging in patients with retinal diseases.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with retinal vein occlusion.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with neovascular age-related macular degeneration, dry age-related macular degeneration, and geographic atrophy.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with diabetic eye disease.
In this podcast, expert clinicians will discuss best practices for reducing ocular toxicities in myeloma patients through the multidisciplinary team.
In this podcast, expert clinicians will discuss strategies to mitigate and manage ocular toxicities related to multiple myeloma therapy.
In this podcast, expert clinicians will discuss the frequency and identification of ocular toxicities of patients on myeloma therapy.
In this podcast, expert clinicians will discuss the mechanisms behind ocular toxicities that have been associated with antibody drug conjugates used for cancer treatment.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Arshad Khanani discuss the efficacy and safety of therapies targeting Ang-2 in nAMD.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Judy Kim discuss the Tie2 pathway and its role in the pathophysiology of retinal vascular diseases.
In this podcast, expert clinicians will discuss best practices regarding the use of Port Delivery System with ranibizumab.
In this educational podcast, experts discuss emerging therapies for their ability to improve outcomes in patients with ocular surface disease. Faculty also review the safety and efficacy data to support new and emerging treatment options for OSD.
This educational podcast will review important considerations for the diagnosis and management of ocular surface disease (OSD) in special patient populations. Faculty will provide pearls for preventing and managing OSD in individuals at elevated risk, including those undergoing ocular surgery, those with glaucoma or diabetes, as well as individuals on medications known to disrupt the ocular surface.
In this podcast, expert clinicians will discuss emerging therapies and the clinical data supporting their use in rare inherited retinal diseases. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/ophthalmology/20251031/10the-retina-radar-with-dr-arshad-khanani-christina-kay
In this podcast, expert clinicians will discuss the clinical data and real-world outcomes of biosimilars in treating retinal diseases. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/ophthalmology/20251031/11the-retina-radar-with-dr-arshad-ashish-sharma
In this podcast, expert clinicians will discuss the latest clinical trial data, including the efficacy and safety, of gene therapies for retinal diseases. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/ophthalmology/20251031/12the-retina-radar-with-dr-arshad-avery-and-pieramici
In this podcast, expert clinicians will discuss the latest data and clinical trial designs for oral and systemic treatments in GA. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/ophthalmology/20250930/8the-retina-radar-with-dr-arshad-khanani-and-vajzovic